J&J Celebrates Simponi Approval With Schering – For Now
This article was originally published in The Pink Sheet Daily
Executive Summary
As Schering waits to see if partner J&J will challenge Merck merger, FDA clears once-monthly follow-on to Remicade.
You may also be interested in...
Remicade: A Study In Translational Looping
The lifecycle of J&J’s TNF inhibitor Remicade – a “pipeline in a product” – highlights how the company used the knowledge gained from one product to improve and expand its portfolio.
NICE Gives Thumbs Down to Simponi--For Now
The controversial health technology assessment agency is unconvinced of the drug's cost benefit in a crowded market, which is already well served, and concerned about its long-term safety profile.
NICE Gives Thumbs Down to Simponi--For Now
The controversial health technology assessment agency is unconvinced of the drug's cost benefit in a crowded market, which is already well served, and concerned about its long-term safety profile.